



AMENDMENTS TO THE CLAIMS:

Claims 1-31 (canceled).

Claim 32 (currently amended and reformatted): A **stability-enhanced** pharmaceutical formulation **of comprising** a benzamide derivative represented by the formula (1):



wherein A represents a structure shown by any one of the formula (2):




or a pharmaceutically acceptable salt thereof, **comprising:**

said benzamide derivative; and

at least one **stability-enhancing compound** selected from the group consisting of D-mannitol, sodium carboxymethyl starch, hydroxypropyl cellulose, magnesium stearate, partly pregelatinized starch, hydroxypropylmethyl cellulose, dimethylacetamide, sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, ammonia, monosodium fumarate, sodium dehydroacetate, sodium erythorbate, **and** trisodium citrate and an amino compound.

Claim 33 (previously presented): The pharmaceutical formulation according to claim 32 wherein said benzamide derivative is represented by the formula (3):



Claim 34 (previously presented): The pharmaceutical formulation according to claim 32 wherein said amino compound is at least one selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatine, sodium glutamate, glycine, L-arginine, L-glutamate and carbachol.

Claim 35 (previously presented): The pharmaceutical formulation according to claim 32 further comprising at least one selected from sodium alginate and a solvent.

Claim 36 (previously presented): The pharmaceutical formulation according to claim 35 wherein said solvent is at least one selected from polyethylene glycol and propylene glycol.

Claim 37 (previously presented): The pharmaceutical formulation according to claim 32 wherein the formulation is a solid formulation which comprises granules prepared by a dry granulation method.

Claim 38 (previously presented): The pharmaceutical formulation according to claim 32 wherein the formulation is a liquid formulation and pH is adjusted within the range of 4 to 12.